Efficacy of Tiotropium in COPD Patients with FEV1 ≥ 60% Participating in the UPLIFT® Trial

Figures & data

Figure 1.  Disposition of tiotropium and control patients with FEV1 ≥ 60% predicted normal.

Table 1.  Baseline characteristics of patients with post-bronchodilator FEV1 ≥ 60% predicted in the UPLIFT® trial

	Tiotropium (N = 632)	Control (N = 578)
Age, years	64 (9)	64 (9)
Male,%	72	68
Pre-bronchodilator
FEV1, L	1.51 (0.37)	1.49 (0.37)
FEV1,% predicted	54 (7)	54 (7)
FVC, L	3.03 (0.81)	3.03 (0.84)
Post-bronchodilator
FEV1, L	1.79 (0.37)	1.78 (0.38)
FEV1,% predicted	64 (3)	64 (3)
FVC, L	3.44 (0.83)	3.46 (0.89)
Body mass index, kg/m2	27 (5)	26 (5)
Smoking history
Current smokers,%	29	36c
Pack-years	49 (28)	46 (26)
COPD duration, years	9.6 (7.7)	9.4 (7.6)
Concomitant medications,%
LABAa	52	53
ICSa	55	54
LABA + ICS	42	42
Anti-cholinergicsb	35	36
SGRQ total score, units	40 (17)	40 (17)

Data are mean (SD) unless otherwise indicated. aUsed alone or in combination. bIncludes short- or long-acting anti-cholinergics. cSignificantly higher percentage than that for the tiotropium group (P = 0.011; χ2).

COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; ICS = inhaled corticosteroid; LABA = long-acting β2-agonist; SGRQ = St George's Respiratory Questionnaire; UPLIFT® = Understanding Potential Long-term Impacts on Function with Tiotropium.

Figure 2.  Pre- and post-bronchodilator FEV1 (A) and FVC (B) over 4 years in the tiotropium and control groups with FEV1 ≥ 60% predicted normal.

Figure 3.  St George's Respiratory Questionnaire total score over 4 years in the tiotropium and control groups with FEV1 ≥ 60% predicted normal.

Figure 4.  Probability of first exacerbation in the tiotropium and control groups with FEV1 ≥ 60% predicted normal.

Figure 5.  Probability of death (any cause) in the tiotropium and control groups with FEV1 ≥ 60% predicted normal.